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Abstract 
Objectives: To describe the clinical outcome and safety of rituximab (RTX) treatment 
in systemic lupus erythematosus (SLE) patients with severe manifestations or 
refractory to standard immunosuppressive therapy, treated at a single center.  
Methods: This was a retrospective analysis of all patients with SLE treated with RTX 
at one center between June 2000 and December 2013. The clinical outcome was 
assessed by determining BILAG scores, anti dsDNA and C3 levels before and six 
months after RTX treatment. For safety analysis, adverse events and deaths were 
recorded. 
 Results: Of a total of 115 patients, 93.9% were female; mean age at diagnosis was 
26.39±11.90 years: mean disease duration at first RTX treatment was 91.96±84.80 
months. A BILAG score variation of -11.26±11.38 (p<0.001) was recorded six months 
after first RTX treatment; 40% of patients had a complete response and 27% had a 
partial response; in 36.5% of patients, C3 levels increased over 25%, and in 33.5% 
dsDNA levels decreased over 50%. Depletion of CD19+ cells was achieved in 94.0% 
of patients. Hypogammaglobulinemia was detected in 14.9% of patients, with 
significant reduction for IgM (p<0.001) and IgG (p=0.001) levels. Severe infections, 
infusion-related and hypersensitivity reactions occurred in 7%, 3.5% and 2.6% of 
patients. Of the 115 patients, 62 patients had repeated RTX treatments, with an 
average number of 1.95±1.17 cycles per patient and a mean interval between 
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infusions of 21.44±20.11 months. At the end of follow-up, 11 patients were deceased; 
6 had cardiovascular events. 
Conclusion: RTX treatment was effective in decreasing disease activity, with low 
incidence of adverse effects. 
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Significance and Innovations 
• There is a notable absence of long-term follow-up studies about lupus patients 
treated with B-cell depletion [BCD] using Rituximab.  
• We address this gap providing up to 14 years of follow-up data on >100 SLE 
patients that we have treated with BCD. To our knowledge, this is the largest 
single center experience ever reported. 
• Rituximab was an effective and safe alternative in the treatment of patients 
with severe or refractory SLE, demonstrating that, although not formally 
approved, it should remain an option in the treatment of such patients. 
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Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disorder, which may 
potentially affect any organ, by inducing the production of pathogenic autoantibodies 
directed against cell components and the deposition of immune complexes. The 
therapeutic approach relies on the use of corticosteroids and other 
immunosuppressive agents, depending on the disease features. However, the 
rationale for the use of those agents comes mainly from uncontrolled studies, and 
only in 2008 a EULAR task force gathered some evidence-based core 
recommendations on the management of SLE1. More recently, the first treat-to-target 
recommendations were published2; however, the role of the available therapies was 
not discussed.Rituximab (RTX) is a chimeric monoclonal antibody that targets CD20 
Page 6 of 54
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
7 
 
positive B cells, directly inducing apoptosis or promoting antibody or complement 
dependent cell toxicity3.  
Two double-blind controlled trials have assessed the efficacy of RTX in the treatment 
of SLE.  
The EXPLORER trial4 was a phase II/III randomized, double-blind, placebo-controlled 
trial, which evaluated the efficacy and safety of RTX against placebo in the treatment 
of 257 patients with moderate to severe SLE, excluding lupus nephritis patients. 
Although a significant improvement was noted in immunologic parameters such as 
CD19+ B lymphocyte count, anti dsDNA antibody levels and complement level in 
RTX-treated patients, the study failed to meet the primary endpoint of superiority of 
RTX. 
The LUNAR trial5, a phase III randomized controlled trial, evaluated the efficacy of 
RTX in the treatment of 144 patients with class III/IV lupus nephritis, concomitantly 
with mycophenolate mofetil (MMF) and corticosteroids or versus MMF, 
corticosteroids and placebo. As in the EXPLORER trial4, RTX achieved B cell 
depletion and improvement in anti dsDNA antibody and complement levels, but 
showed no superiority of RTX. 
However, a review6 and many further retrospective and open label studies7-11 
suggested that RTX is effective and safe in the treatment of moderate to severe SLE 
when standard treatments have failed. Some recent studies showed RTX might be a 
useful steroid-sparing agent in patients with lupus nephritis12-13 and in newly 
diagnosed patients14. 
RTX was first used as an alternative in the treatment of refractory SLE at University 
College London Hospital in 2000; the clinical outcome of the first fifty patients was 
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published in 20097, as well as a later assessment looking at the outcome in relation 
to duration of B-cell depletion15. 
The objective of this retrospective study was to examine data on the efficacy and 
long-term safety of RTX in patients with lupus at this center over a 14-year period of 
time.  
 
Patients and methods 
Study Design 
This is a single center in-depth retrospective analysis of all patients diagnosed with 
SLE treated with RTX at the University College of London Hospital (UCLH), between 
June 2000 and December 2013 and followed for up to 14 years. 
 
Participants 
We enrolled the patients through the UCLH Rheumatology Unit database of all the 
SLE patients treated with RTX. 
The treatment protocol consisted on two infusions of 1 g of RTX, two weeks apart, 
with a combination of methylprednisolone (100–250 mg), anti-histamines and, up to 
2007, 500–750 mg of cyclophosphamide. After 2007 we reduced the 
cyclophosphamide to a single infusion (following the first dose of RTX). Following B-
cell depletion [BCD] the patients continued on hydroxychloroquine and, wherever 
possible, a reducing dose of corticosteroids. Invariably any immunosuppressive 
drugs being prescribed at the time of BCD were stopped until the B-cells had 
returned and the patients started to flare. CD19 counts and total immunoglobulin 
levels were monitored approximately every 2 months post-BCD until the CD19+ B-cell 
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count was back to normal. As this study is an audit, it did not require hospital ethics 
committee approval.  
 
Data collection 
The clinical records of all patients enrolled were reviewed for gender, ethnicity, age at 
presentation, disease duration at first RTX treatment, previous immunosuppressant 
treatments, indication for RTX treatment, response to RTX treatment after 6, 12, 18 
and 24 months, follow-up time after RTX treatment. 
Other data collected included anti dsDNA antibody and C3 levels before and 6 
months after RTX infusions. Both parameters were measured at the UCLH 
laboratory. Anti-dsDNA titers were evaluated by ELISA [n <50 u/ml]and C3 levels [n = 
0.9 → 1.8mg/l] by laser nephelometry. 
Data on BCD was also recorded: acknowledgement of BCD in the first 6 months after 
RTX treatment was reviewed. 
Adverse events, including allergic/anaphylactic reactions, hypogammaglobulinemia, 
infections, cardiovascular and cerebrovascular events and death were reviewed. 
 
Measurements and calculations 
The indication for RTX treatment was dependent upon the severity of the 
organ/system involved (which was captured by BILAG assessments). 
For the purpose of clinical outcome assessment, response to RTX treatment was 
classified according to the ‘classic’ BILAG score: full disease response being 
determined when BILAG A or B scores changed to C or D in every organ system; 
partial response if BILAG scores changed from A or B to C or D score in at least one 
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organ system but with a persistent A or B score in another organ system; no 
improvement when a BILAG A or B score remained unchanged after treatment. 
For anti-dsDNA antibody levels, the benefit of RTX treatment was recorded when a 
50% reduction of the initial titer was achieved. For the C3 levels, benefit was 
recorded if a 25% increase occurred.  
Regarding safety analysis, the proportion of patients with adverse reactions was 
recorded. Adverse events were divided into the following categories: severe 
infections (defined as requiring hospitalization or intravenous antibiotics), 
hypersensitivity reactions, infusion-related reactions and others. Hypersensitivity 
reactions occur when the drug is recognized as an antigen by the patient immune 
system; these are IgE-mediated reactions and, as such, only become evident with 
subsequent exposures to the culprit drug. Clinically, hypersensitivity reactions lead to 
urticarial, rash, angioedema, bronchospasm, hypotension, and eventually 
anaphylaxis. Infusion reactions usually develop during the infusion or several hours 
afterwards, have a mild to moderate intensity and are characterized by a complex of 
chills, fever, nausea, asthenia, headache, hypotension; these reactions are thought 
to be cytokine-dependent16. Hyponatremia-induced seizures due to 
cyclophosphamide, reactivation of hepatitis B, jugular thrombosis due to 
catheterization, abnormal liver function tests or cyclophosphamide-induced 
cytopenias were classified as other adverse reactions. 
  
Statistical Analysis 
Descriptive statistics was performed in terms of mean and standard deviation in 
continuous variables, and in percentage with 95% confidence interval in case of 
discrete variables.  
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Statistical analysis was performed using IBM SPSS® version 22.0 software. We 
applied paired samples Student’s t-test to compare the values of the continue 
variables before and after RTX treatment; ordered and multinomial logistic regression 
analysis were performed to compare the number of infusions according to BILAG 
system involved and BILAG responses after RTX treatment in the different organ 
involvment. Both models included all the BILAG systems. . 
We considered statistical significance at p < 0,05. 
 
Results:  
Baseline characteristics 
Out of a total of 650 patients with an SLE diagnosis, 115 patients treated with RTX 
were identified after reviewing the available charts. 
The baseline demographic and clinical characteristics of the patients are described in 
table 1. 
Female gender and Caucasian ethnicity were predominant. Prednisolone and 
hydroxichloroquine were the most frequent previous treatments (94.8% and 70.3%, 
respectively), followed by azathioprine, mycophenolate mofetil, cyclophosphamide, 
and methotrexate; other less frequent previous therapies included cyclosporine A, 
intravenous immunoglobulin, dapsone, sulphassalazine, and plasma exchange.  
The main disease features that motivated RTX treatment were musculoskeletal, 
mucocutaneous and renal involvement. Although there were 54 patients that scored 
A or B for hematological manifestations of the disease, most of them had mild to 
moderate anemia or slightly low leukocyte count, not demanding aggressive 
intervention. 
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Mean follow up time after the last RTX cycle was 46.03±41.10 months; four patients 
were lost to follow-up. 
 
Rituximab infusions 
In the considered interval, among the 115 patients who had RTX treatment, 53 had 
only one cycle of RTX; 35 had two cycles; 14 had three cycles; and 9, 1 and 3 
patients had, respectively, 4, 5 and 6 cycles. The mean number of RTX cycles was 
1.95±1.18. 
Mean interval between the 1st and the 2nd cycles of RTX was 23.81±22.65 months. 
Overall mean interval between two consecutive cycles was 21.75±20.23 months. 
None of the indications for the first rituximab treatment was associated with a higher 
number of RTX cycles (p=0.691). 
The reason that led to the second RTX treatment was the same as had led to the first 
in 85.2% (CI95%: 76.3-94.1%) of patients. Overall, the principal involvement that 
motivated re-treatment with RTX (N=109) was the same that had led to previous 
treatment in 79.8% (CI95%: 72.3-87.4%) of cases; in 17.4% of cases, the new flare 
was distinct from the ones that were previously responsible for RTX treatment and a 
new RTX cycle was administered to prevent new flares in 2.8% of the cases. 
Efficacy 
There was a significant decrease in BILAG score after treatment with RTX, both at 
first and subsequent cycles. The addressed serological markers of disease also 
demonstrated a significant improvement, as revealed on tables 2 and 3. 
Reviewing the RTX treatment, of the six patients who were not successfully CD19+ 
lymphocyte depleted, only one had no response; partial and complete responses 
were observed in three and two patients, respectively. Overall, absence of depletion 
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and absence of response were coincident in 7 of the 15 patients who were not 
successfully depleted. 
For RTX re-treatments (N=100), in 48% (CI95%: 38.2-57.8%) of cases, patients were 
still partially depleted of CD19+ lymphocytes at the time of the new cycle. 
The response to therapy according to the different organs affected is shown on table 
4. Musculoskeletal and renal manifestations were associated with higher response 
rate in our model (p=0.026 and p=0.001, respectively). 
 
Rituximab effects on immunoglobulins (Ig A, M, G) 
With respect to the first RTX treatment, a statistically significant decrease 6 months 
post-treatment was found both in IgM (1.26±1.05 g/L [0 months], 0.94±0.97 g/dL [6 
months], p<0.001) and IgG levels (15.15±6.92 g/L [0 months], 13.52±6.84 [6 months], 
p<0.001). No such difference was found for IgA (p=0.112). At six months after first 
RTX cycle, low levels of IgA, IgG and IgM were detected, respectively, in 2.1% 
(CI95%: 0.0-5.0%), 14.9% (CI95%: 7.7-22.1%)  and 23.4% (CI95%: 14.8-32.0%) of 
patients (N=94). 
Considering all RTX cycles, only IgM levels decreased significantly after 6 months 
(1.22±1.02 g/L to 0.92±0.92 g/L, p <0.001); and low IgA, IgG and IgM levels were 
identified, respectively, in 3.3% (CI95%: 0.7-5.9%), 12.2% (CI95%: 7.7-17.0%) and 
27.2% (CI95%: 20.7-33.7%) of patients (N=180). 
 
Adverse events 
Adverse events are presented on table 5. 
Four severe infections occurred in patients with low IgM levels: three infections 
occurred within six months after first RTX cycle (one had a soft tissue infection, one 
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gastroenteritis and one septic shock of unknown origin) and one was registered after 
the second RTX cycle (cystitis). Human anti-chimeric antibodies were identified in 
two patients — although they were not routinely investigated. 
Overall, among the 224 RTX infusions, in 80.4% (CI95%: 75.2-85.6%) no adverse 
events were recorded. 
From 2000 to 2013, six patients had at least one cardiovascular event: one patient 
presented with stroke; four patients had a myocardial infarction. 
During the same period, eleven patients deceased: three patients died due to 
disease activity; two patients committed suicide; one patient had a fatal acute 
respiratory distress syndrome attributed to cyclophosphamide infusion; one patient 
had a fatal cerebrovascular accident; one patient had a fatal myocardial infarction; 
and the cause of death was unknown in three patients. 
 
Discussion 
Although the use of B-cell depletion in lupus in not novel, there is a marked paucity of 
long-term follow-up data on patients treated in this way. This study attempts to fill the 
gap by providing ‘real world’ experience on >100 lupus patients followed for periods 
of up to 14 years. 
To our knowledge, this report analyses the largest single-center experience of the 
use of rituximab in SLE. 
Edwards and Cambridge, were the first to suggest that since corticosteroids, 
cyclophosphamide and RTX were able to reduce peripheral B-cell numbers, BCD 
might best be achieved by combining these drugs [16]. Their studies in patients with 
rheumatoid arthritis fully validated this approach [17] and we extended its use to 
patients with lupus. [8, 14] 
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In this cohort, the efficacy analysis was largely favorable. Most of the patients treated 
with RTX at UCLH presented with clinical features refractory to more than one 
immunosuppressive agent; however, a small minority, in recent years, was treated 
with RTX at the time of diagnosis, in patients with florid presentation of the disease or 
severe renal involvement. In any case, RTX was able to reduce disease activity, with 
a response rate (partial or complete response) of about 70%. The response to RTX 
was better in those patients with musculoskeletal and renal involvement. These data 
are in line with recent evidence suggesting that RTX is useful, not only in cases of 
lupus nephritis refractory to standard immunossuppressive agents, but also as a 
steroid sparing agent in the induction of remission12-13,19-23. 
Notably, many of the patients who flared and needed to be re-treated with RTX were 
still partially depleted of CD19+ lymphocytes by the time of flare. 
The safety profile was also favorable, with a low incidence of serious adverse events; 
in particular no patient developed multifocal leukoencepalopathy but there were 
serious infections, one case of reactivation of hepatitis B and one death due to an 
acute respiratory distress syndrome secondary to cyclophosphamide infusion. The 
infusion related and hypersensitivity reactions were mostly mild to moderate. 
The limitations of this study have to be carefully taken into account. The cohort was 
highly heterogeneous in terms of affected systems, and interobserver variability has 
to be considered when judging BILAG scores. However, all the clinicians making the 
BILAG assessments were trained by one of us (DAI) and the single centre approach 
allows for uniformity of serological assessment. Disease duration also showed wide 
variability, as well as the number of previous immunosuppressive agents used. 
There were some missing data, for several reasons. Firstly, four patients were lost to 
follow up. Some patients were not seen in the outpatient clinic at six months, 
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therefore, clinical and laboratory data could not be easily obtained for that period. In 
some cases, laboratory tests were not available. Another limitation was that some 
patients (n=4) had the last RTX cycle less than six months before data collection. 
The absence of a control group also limits the measure of efficacy and safety of RTX 
in SLE patients. 
Even though a new anti-BlyS monoclonal antibody, belimumab, has been approved 
for the treatment of SLE, its role in the treatment of lupus nephritis and 
neuropsychiatric features has not yet been established. Long term data on efficacy 
and safety are still lacking for this drug.  
Rituximab is the biologic agent with the most extensive off-label use in the treatment 
of refractory SLE and observational studies. Much published data seem to contradict 
the results from the two available randomized controlled trials4,5, suggesting a 
possible role for this drug in the treatment of SLE patients. It is notable that both the 
American College of Rheumatology and the European League Against Rheumatism 
guidelines on the treatment of lupus nephritis consider rituximab a viable therapeutic 
option24,25. 
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Table 1. Baseline demographic and clinical characteristics of the SLE 
patients treated with RTX. 
Epidemiological features 
Gender (Female:Male)  
Ethnicity (n) 
Caucasian    
Afro-Caribbean 
South Asian 
Other 
Mean age at diagnosis (mean ± SD, years)   
Mean disease duration at first RTX treatment 
(mean ± SD, months) 
Previous treatments (n,[%]) 
Prednisolone 
Hydroxichloroquine 
Azathioprine  
Mycophenolate mofetil  
Cyclophosphamide 
Methotrexate 
 
108:7 
 
50 
37 
20 
8 
26.39±11.90 
92.00±84.80 
 
 
109 (94.8%) 
90 (70.3%) 
74 (64.3%) 
40 (34.8%) 
39 (33.9%) 
35 (30.4%) 
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Others 
Serological characterization (n,[%]) 
Positive antinuclear antibodies  
Positive anti-Ro antibodies 
Positive anti-La antibodies 
Positive anti-RNP antibodies 
Positive anti-Sm antibodies 
Positive anti-cardiolipin antibodies 
Anti dsDNA antibodies 
Lupus anticoagulant 
Clinical features: all BILAG score A and B (n) 
General   A 
   B  
Mucocutaneous   A  
   B  
Neurological   A  
   B  
Musculoskeletal   A  
   B  
Cardiovascular and respiratory  A  
   B  
Vasculitis   A  
   B  
Renal   A  
   B  
21 (18.3%) 
 
111 (96.5%) 
62 (53.9%) 
23 (20%) 
53 (46.1%) 
32 (27.8%) 
21 (18.3%) 
81 (70.4%) 
12 (10.4%) 
 
10 
23 
12 
29 
8 
4 
23 
32 
8 
7 
3 
5 
15 
23 
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Haematological   A  
   B  
Disease activity 
Mean BILAG score (mean±SD) 
Mean anti dsDNA (mean±SD, unit) (n < 50 U/ml) 
    Mean C3 (mean±SD, unit) (n = 0.9 -1.8mg/L) 
8 
46 
 
18.29±10.62 
712.60±1410,80 
0.79±0.34 
Table 2. Mean BILAG score, C3 level and dsDNA titer at baseline and 6 months 
after RTX therapy. 
 1st RTX cycle  
 Baseline After 6 months  ∆ p 
BILAG score 
(N=109) 
18.29±10.62 6.79±5.55 -11.22±11.330 p<0.001 
C3 (N=103) 0.79±0.03 0.95±0.03 0.16±0.03 p<0.001 
Anti dsDNA 
(N=105) 
712.60±1410.80 478.06±1572.33 -243.36±141.32 p<0.001 
 Any RTX cycle 
 Baseline After 6 months  ∆ p 
BILAG score 
(N=206) 
16,18±8,91 6,83±4,95 -9,23±10,45 p<0.001 
C3 (N=192) 0.89±0.36 0.96±0.33 0.20±1.16 p<0.001 
Anti dsDNA 
(N=199) 
619.73±1197.61 486.60±1461.16 -125.56 
±1237.30 
p<0.001 
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Table 3. Response rate to therapy in terms of BILAG score, C3 level, anti dsDNA 
titer and depletion of CD19+ lymphocytes. 
 1st RTX cycle (at 6 
months), % (95% CI) 
All RTX cycles (at 6 
months), % (95% CI) 
% of patients with a 
decrease in anti dsDNA level 
≥50% or normalization  
38.2% (28.9-47.5) 37.7% (30.8-44.6) 
% of patients with an 
increase in C3 level ≥25% or 
normalization  
36.5% (27.2-45.8) 31.8% (25.5-38.1) 
% of patients with complete 
response  
43.0% (33.7-52.3) 42.4% (35.7-49.1) 
% of patients with partial 
response  
29.0% (20.5-37.5) 27.3% (21.2-33.4) 
% of patients with no 
response  
28.0% (19.6-36.4) 30.2% (23.9-36.5) 
% of patients successfully 
CD19+ lymphocytes 
depleted (N=100)   
94.0% (89.3-98.7) 92.0% (88.2-95.8) 
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Table 4. Changes in BILAG scores in responders to RTX treatment. 
 General Mucocutaneous Neurologic Musculoskeletal Cardiorrespiratory Vascular Renal Hematologic 
Total A/B 33 41 12 55 15 8 38 54 
A → B 0 2 0 6 0 0 7 3 
A → C 7 4 2 7 1 2 6 2 
A → D 2 3 2 5 6 1 1 2 
B →C 
 
9 11 0 13 0 0 11 21 
B →D 13 13 4 15 4 5 10 6 
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Table 5. Adverse events occurring 6 months within RTX therapy. 
Adverse event 1st RTX 
infusion 
(n= 115) 
2nd RTX 
infusion 
(n = 62) 
3rd RTX 
infusion 
(n= 27) 
4th RTX 
infusion 
(n= 13) 
5th RTX 
infusion 
(n= 4) 
6th RTX 
infusion 
(n= 3) 
Severe 
infections 
8 5 0 0 0 0 
Hypersensitivity 
reactions 
3 5 4 1 0 0 
Infusion-related 
reactions 
4 6 1 1 0 1 
Other 10 11 0 1 1 0 
None 91 51 23 10 3 2 
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